NCT05914623

Brief Summary

The purpose of this study was to investigate the effect of high-frequency repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with cerebral small vessel disease.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 6, 2023

Completed
16 days until next milestone

First Posted

Study publicly available on registry

June 22, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

June 25, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2024

Completed
Last Updated

February 29, 2024

Status Verified

February 1, 2024

Enrollment Period

9 months

First QC Date

June 6, 2023

Last Update Submit

February 27, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • phase difference (PD) in degree

    A cerebral autoregulation parameter derived from transfer function analysis. Continuous cerebral blood flow velocities of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler. Spontaneous arterial blood pressure will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size. Transfer function analysis will be used to derive the cerebral autoregulatory parameter.

    0-5 days

Study Arms (2)

rTMS

ACTIVE COMPARATOR

Patients are treated with repetitive transcranial magnetic stimulation (rTMS).

Procedure: Repetitive transcranial magnetic stimulation

sham-rTMS

PLACEBO COMPARATOR

Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).

Procedure: Sham repetitive transcranial magnetic stimulation

Interventions

After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).

rTMS

After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.

sham-rTMS

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-80 years, regardless of gender;
  • Diagnosed with CSVD, and neuroimaging presented as recent small subcortical infarcts;
  • Initiated transcranial magnetic stimulation within 7 days of onset;
  • Subject or legal representative agreed to the treatment and signed the informed consent;

You may not qualify if:

  • Vascular stenosis \> 50% diagnosed by Transcranial Doppler (TCD) and carotid ultrasound;
  • Previous history of atrial fibrillation or myocardial infarction within 6 months;
  • Moyamoya disease or hereditary cerebral small vessel disease, such as CADASIL;
  • White matter hyperintensities (WMH) of non-vascular origin;
  • Severe hepatic and renal diseases, cancer or other major diseases related to integral medical and surgical procedures;
  • Patients with contraindications to transcranial magnetic stimulation, such as metal or electronic devices in the brain;
  • Pregnant or breastfeeding women;
  • The patients with disorders of consciousness, agitation or insufficient bilateral temporal bone windows for insonation who cannot cooperate to dynamic cerebral autoregulation monitoring;
  • Previous history of epilepsy or family history of epilepsy;
  • Previous treatment with transcranial magnetic stimulation or its equivalent;
  • Unwillingness to be followed up or poor adherence to treatment;
  • Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment, or who have participated in this study;
  • Other conditions that the investigators deemed unsuitable for enrollment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Hospital of Jilin University

Changchun, Jilin, China

RECRUITING

MeSH Terms

Interventions

Transcranial Magnetic Stimulation

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Central Study Contacts

Yi Yang, MD,PhD

CONTACT

Zhenni Guo, MD,PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Vice President of First Hospital of Jilin University

Study Record Dates

First Submitted

June 6, 2023

First Posted

June 22, 2023

Study Start

June 25, 2023

Primary Completion

April 1, 2024

Study Completion

July 1, 2024

Last Updated

February 29, 2024

Record last verified: 2024-02

Locations